Gordon 2006.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 220, breast, non‐myeloid hematological malignancies, gastrointestinal, genitourinary, lung, gynecological, other cancer (stage I‐IV); no anticancer therapy
Interventions	drug = Darbepoetin alpha dose = 6.75 µg/kg sc Q4W hb‐target = 12‐13 g/dL planned ESA duration = 16 weeks
Outcomes	Primary: Hb response; secondary: transfusion, Hb change, QoL, safety
Notes	study number = 65772
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	randomization list will be centrally generated by Amgen
Allocation concealment?	Low risk	central randomization